Trial · NCT07912710
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 34 of 34
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Plasma phosphorylated tau 217 (p-tau217) concentration | Baseline and follow-up assessments (up to 50 years) | Plasma p-tau217 concentration is measured in participants with available plasma samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Plasma total tau (t-tau) concentration | Baseline and follow-up assessments (up to 50 years) | Plasma t-tau concentration is measured in participants with available plasma samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Plasma neurofilament light chain (NfL) concentration | Baseline and follow-up assessments (up to 50 years) | Plasma NfL concentration is measured in participants with available plasma samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Plasma glial fibrillary acidic protein (GFAP) concentration | Baseline and follow-up assessments (up to 50 years) | Plasma GFAP concentration is measured in participants with available plasma samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid amyloid-β 1-42 (Aβ1-42) concentration | Baseline and follow-up assessments (up to 50 years) | CSF Aβ1-42 concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid amyloid-β 1-40 (Aβ1-40) concentration | Baseline and follow-up assessments (up to 50 years) | CSF Aβ1-40 concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid amyloid-β 1-42/1-40 ratio (Aβ1-42/Aβ1-40) | Baseline and follow-up assessments (up to 50 years) | The CSF Aβ1-42/Aβ1-40 ratio is calculated from measured CSF concentrations (unitless). Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid phosphorylated tau 181 (p-tau181) concentration | Baseline and follow-up assessments (up to 50 years) | CSF p-tau181 concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid phosphorylated tau 217 (p-tau217) concentration | Baseline and follow-up assessments (up to 50 years) | CSF p-tau217 concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid total tau (t-tau) concentration | Baseline and follow-up assessments (up to 50 years) | CSF t-tau concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid neurofilament light chain (NfL) concentration | Baseline and follow-up assessments (up to 50 years) | CSF NfL concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Cerebrospinal fluid glial fibrillary acidic protein (GFAP) concentration | Baseline and follow-up assessments (up to 50 years) | CSF GFAP concentration is measured in participants with available CSF samples. Longitudinal changes are evaluated when repeated measurements are available. |
| Secondary | Regional brain atrophy assessed by structural MRI | Baseline and follow-up assessments (up to 50 years) | Regional brain atrophy is assessed using structural MRI in participants with available imaging data. Longitudinal changes are evaluated when repeated scans are available. |
| Secondary | Cerebral amyloid-β burden assessed by PET | Baseline and follow-up assessments (up to 50 years) | Cerebral amyloid-β deposition is assessed using amyloid PET in participants with available imaging data. Longitudinal changes are evaluated when repeated scans are available. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912710/registered?page=2